Zydus Lifesciences has launched VaxiFlu-4, India’s first quadrivalent influenza vaccine tailored for the 2025 Southern Hemisphere flu season. This vaccine aligns with the World Health Organization’s (WHO) recommended composition, offering comprehensive protection against four influenza virus strains:
A/Victoria/4897/2022 (H1N1)pdm09-like virus: A strain of the H1N1 subtype, known for causing respiratory illnesses.
A/Croatia/10136RV/2023 (H3N2)-like virus: A variant of the H3N2 subtype, associated with severe flu seasons.
B/Austria/1359417/2021 (B/Victoria lineage)-like virus: Belonging to the B/Victoria lineage, this strain contributes to seasonal flu cases.
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus: Part of the B/Yamagata lineage, another significant contributor to influenza infections.
The introduction of VaxiFlu-4 underscores Zydus’s commitment to public health by providing broader protection against prevalent influenza strains. Quadrivalent vaccines like VaxiFlu-4 cover both influenza A and B strains, reducing the risk of vaccine mismatch and enhancing overall efficacy.
